Aniracetam is a synthetic "racetam" drug in the same family as piracetam. It has been used clinically for behavioral symptoms of dementia, but it is not approved for human use in the US and is sold online in "nootropic" products.
Also known as: racetam, Ro 13-5057.
There is no FDA-approved aniracetam product. A 2021 study (Cohen) gave the typical pharmacologic dose as 200 to 750 mg and found up to 502 mg per serving in a supplement it tested. These are study protocols, not a recommendation.
Aniracetam is not approved for human use in the United States (Cohen 2021). A 2023 review (Jędrejko) found that what counts as a legal "nootropic" ingredient varies widely between countries.
When researchers bought and tested 10 cognitive-enhancement supplements labeled as containing racetams (Cohen 2021), they found aniracetam along with other unapproved drugs, including some not declared on the label; 9 of 12 declared amounts were inaccurate, and one product could expose a user to up to four unapproved drugs at once.
Evidence in people is thin. A 2002 review (Nakamura) describes aniracetam's clinical use for behavioral and psychological symptoms of dementia after stroke and in Alzheimer's disease, but most of its findings come from rodent models, and the review says there is no convincing evidence that the promising animal results will carry over to people.
We could not find a single published half-life or time to peak for aniracetam that applies to a supplement dose, so we do not list one. The 2002 review (Nakamura) notes that its breakdown products may account for part of its effects.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator